Access our fourth-quarter and full-year 2022 financial results.

Gilead Sciences, Inc business logo
Medicine Questions
Report an Adverse Event
Investors
Contact
Global Operations
North America
  • Canada
  • Mexico
  • USA
South America
  • Argentina
  • Brazil
Asia
  • China Mainland
  • Hong Kong
  • India
  • Japan
  • Korea
  • Singapore
  • Taiwan
Middle East
  • Israel
  • Saudi Arabia
  • Türkiye
  • United Arab Emirates
Africa
  • South Africa
Australia
  • Australia and New Zealand
Europe
  • Austria
  • Belgium and Luxembourg
  • Czech Republic & Slovakia
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Iceland
  • Ireland
  • Italy
  • Netherlands
  • Norway
  • Poland & The Baltics
  • Portugal
  • Romania
  • Russia
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom
Gilead Logo
  • Our Company
    Mission and Core Values Leadership Public Policy Engagement Policies and Disclosures U.S. Locations
  • Our Purpose
    Partnerships and Community Corporate Giving Gilead Foundation Inclusion and Diversity Environmental, Social, Governance (ESG) Sustainability Advancing Global Health Medication Access
  • Science & Medicine
    Therapeutic Areas Medicines Pipeline Research Clinical Trials
  • News and Press
    Events Stories Newsroom Company Statements Annual Reports
  • Careers
    Careers at Gilead Our Culture Meet Our Employees Inclusion and Diversity in Hiring Compensation, Benefits and Wellbeing Our Global Footprint Early Career Opportunities Postdoctoral Fellowships Hiring Events Talent Community Sign-up
  • Utility
    Privacy Statements Terms Of Use Social Media Guidelines EU Data Disclosure Sitemap
BACK TO MAIN MENU Leadership Governance and Committees
BACK TO MAIN MENU Public Policy Engagement Political Contributions Archives
BACK TO MAIN MENU Policies and Disclosures Policies Disclosures
BACK TO MAIN MENU Partnerships and Community COMPASS Initiative HepConnect HIV Age Positively Toward Health Equity for Black People Impacted by TNBC RADIAN TRANScend
BACK TO MAIN MENU Corporate Giving What We Fund Funding Requests Zeroing In: Ending the HIV Epidemic
BACK TO MAIN MENU Gilead Foundation Creating Possible Fund
BACK TO MAIN MENU Environmental, Social, Governance (ESG) Reporting U.N. Global Compact U.N. Sustainable Development Goals
BACK TO MAIN MENU Sustainability Our Business Is Sustainable Performance
BACK TO MAIN MENU Advancing Global Health COVID-19 HCV Elimination
BACK TO MAIN MENU Medication Access U.S. Patient Access Disaster Product Replacement Global Access Authorized Distributors
BACK TO MAIN MENU Research Research Scholars Program Compassionate Use Investigator-Sponsored Research
BACK TO MAIN MENU Newsroom Press Releases Media Inquiries
BACK TO MAIN MENU Company Statements Gilead Enables Easier Veklury® (Remdesivir) Access Through Retail and Specialty Pharmacies for Long-Term Care and Skilled Nursing Facilities Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5 Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S. Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products Gilead to Expand Footprint in Oceanside Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B) Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19 Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines
BACK TO MAIN MENU Annual Reports Year in Review 2021
BACK TO MAIN MENU Privacy Statements Cookie Statement Global Applicant Privacy Statement
BACK TO MAIN MENU
North America
  • Canada
  • Mexico
  • USA
South America
  • Argentina
  • Brazil
Asia
  • China Mainland
  • Hong Kong
  • India
  • Japan
  • Korea
  • Singapore
  • Taiwan
Middle East
  • Israel
  • Saudi Arabia
  • Türkiye
  • United Arab Emirates
Africa
  • South Africa
Australia
  • Australia and New Zealand
Europe
  • Austria
  • Belgium and Luxembourg
  • Czech Republic & Slovakia
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Iceland
  • Ireland
  • Italy
  • Netherlands
  • Norway
  • Poland & The Baltics
  • Portugal
  • Romania
  • Russia
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom
BACK TO MAIN MENU

Contact

  • Request Medicines Information
  • Report an Adverse Event
  • Partnership Request
  • Medicine Questions
  • Report an Adverse Event
  • Investors
  • Contact
  • Global Operations
Toggle Inner Dropdown
BACK TO MAIN MENU Google.com
  • Events
  • Stories
  • Newsroom
    • Press Releases
    • Media Inquiries
  • Company Statements
    • Gilead Enables Easier Veklury® (Remdesivir) Access Through Retail and Specialty Pharmacies for Long-Term Care and Skilled Nursing Facilities
    • Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus
    • Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety
    • Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5
    • Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer
    • Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir
    • Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade
    • All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S.
    • Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission
    • Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products
    • Gilead to Expand Footprint in Oceanside
    • Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities
    • Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare
    • Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain
    • Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia
    • Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
    • Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates
    • Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant
    • Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir
    • Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union
    • Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer
    • Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees
    • Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States
    • Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis
    • Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B)
    • Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer
    • Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19
    • Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program
    • Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program
    • Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services
    • Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD
    • Gilead Sciences Statement on Recent Events in Washington, D.C.
    • Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®
    • Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines
  • Annual Reports
    • Year in Review 2021

Press Releases

Filter By Year

2023

February

  • February 02, 2023

    Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
  • February 02, 2023

    Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
  • February 01, 2023

    Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer

January

  • January 30, 2023

    Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
  • January 27, 2023

    Gilead Sciences to Present at Upcoming Investor Conferences
  • January 19, 2023

    Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
  • January 03, 2023

    European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
  • January 03, 2023

    Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies

Filter By Year

Gilead Sciences, Inc business logo

© 1996-2023 Gilead Sciences, Inc. All rights reserved.

AREAS OF INTEREST

  • Careers
  • Environmental, Social, Governance (ESG)
  • Medicines
  • Partnerships and Community
  • Pipeline
  • Stories@Gilead

INFORMATION

  • Contact Us
  • Investor Calls
  • Press Room
  • Report an Adverse Event
  • Sitemap

LEGAL

  • Cookie Statement
  • EU Data Disclosure
  • Modern Slavery Act Statement
  • Privacy Statement
  • Public Policy Engagement
  • Social Media Guidelines
  • Terms of Use

FOLLOW US

  • twitter
  • linkedin
  • Instagram
  • facebook
  • youtube

Headline

Intersititial body copy

Ok Cancel